source
- BMS beats Q2 forecasts and lifts 2026 outlook despite delays in Cobenfy and milvexian dataBMS reported second‑quarter revenue of $12.97 billion, topping analysts' estimate of $11.73 billion, and earnings per share of $2.04, well above the $1.60 consensus. The strong results prompted the…
- Biopharma job postings in New York rise 34% over past year, seven companies now hiringBiopharma employment opportunities in New York appear to be expanding, with job listings on BioSpace increasing 34% between July 2025 and July 2026. Although the number of postings dipped slightly…